A prospective multicenter study of 433 patients demonstrates that combining stereotactic radiotherapy with biological cancer therapy is safe, with severe adverse events occurring in less than 10% of cases. Crucially, continuing biological therapy during radiotherapy does not increase toxicity or compromise survival outcomes.